Top COVID-19 Deals (Part I): Biopharma Drug Development

The recent emergence of the coronavirus SARS-CoV-2 and the COVID-19 pandemic has spurred global healthcare and life sciences companies- as well as government agencies- to partner at an unprecedented speed to develop vaccines- treatments- and tests This article covers last four months of deal data provided by Chris Dokomajilar of DealForma. This first part is…

ByPrince GiriApril 17, 2020

TOP 20

Top Biopharma Deal Terminations of 2018-2019 by Total Value Received

The biopharma industry saw a significant increase in the number of deal terminations in the last two years. Clinical and regulatory results- change in control limitations- and strategic reprioritizations were among the most common reasons for deal termination. We used the DealForma database to track partnership terminations announced in 2018 and 2019. We compiled a list of…

ByPrince GiriJanuary 3, 2020

TOP 20

Top 20 BioPharma Companies based on 2018 Total Revenue

The global pharma companies have been advancing their pipelines with emerging needs of patients. Pharma companies are also focusing on diagnostics & devices- which were emerged as one of major revenue generator in 2018- with the development of new products and devices. The year 2018 also proved to be a record with approval of 55…

ByPrince GiriMay 1, 2019

Top COVID-19 Deals (Part I): Biopharma Drug Development

Top Biopharma Deal Terminations of 2018-2019 by Total Value Received

Top 20 BioPharma Companies based on 2018 Total Revenue

Contact US

FOLLOW US